Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies

Press Release

(3BL Media / theCSRfeed) Seattle, WA – December 8, 2011 – Eli Lilly and Company (NYSE: LLY) announced that it is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis, including multidrug-resistant strains known as MDR-TB.

LillyPad, Our Company Blog: Fighting MDR-TB, Together


October 27th, 2011 | By: David Marbaugh

Bonjour! Greetings from Lille, France, where we just announced the third stage of The Lilly MDR-TB Partnership, our program to help fight against multidrug-resistant tuberculosis – a disease that kills more than 150,000 people each year.

Treatable and preventable – and virtually eradicated in the U.S. – MDR-TB typically afflicts people in low-to middle-income countries. Like the name implies, MDR-TB is resistant to most antibiotics that work against TB.

Video News Release: Lilly Foundation Commits US $30 Million to Fight MDR-TB


The Lilly Foundation has committed US $30 million to The Lilly MDR-TB Partnership over the next five years (2012 to 2016). This funding will be used to advance the partnership's efforts in two key areas of focus: training for health care providers and improving supply and access to safe, effective, and quality-assured second-line medicines. Watch our video news release to see how The Lilly MDR-TB Partership is making a difference in the lives of people and communities most affected by multidrug-resistant tuberculosis.

Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership

Funding continues partnership’s fight against multidrug-resistant tuberculosis
Press Release

(3BL Media / theCSRfeed) Lille, France – October 27, 2011 – The Eli Lilly and Company Foundation has committed US $30 million in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug-resistant tuberculosis, a disease that disproportionately affects developing countries and kills more than 150,000 people each year. The announcement was made ahead of the opening of the 42nd Union World Conference on Lung Health in Lille, France, later this week.


Subscribe to MDR-TB